

Report of the Supervisory Board

Dear Shareholders,

In fiscal year 2020, the Supervisory Board properly fulfilled the tasks incumbent upon it according to the law, the Articles of Association, and the rules of procedure. It continuously monitored the Executive Board and advised it on its corporate management activities. The Supervisory Board was directly involved in all decisions of fundamental importance to the company. The Executive Board regularly, promptly, and extensively informed the Supervisory Board about corporate planning, business performance, and strategic progress, as well as the Group's current situation. The Chairman of the Executive Board also regularly informed the Chairman of the Supervisory Board outside the Supervisory Board's meetings about current developments and significant business transactions. Moreover, the Chairman of the Supervisory Board and the Chairman of the Executive Board liaised on a regular basis on issues related to strategy, planning, general business development, the risk situation, risk management, and compliance. A total of seven Supervisory Board meetings took place during the period under review. The Remuneration Committee convened once during the reporting period. If necessary, the Supervisory Board also issued authorizations by written procedure. Resolutions of fundamental importance were either passed on the basis of relevant documentation or after direct discussions with the Executive Board. The participation at the meetings of the Supervisory Board was 98% and at the meeting of the Remuneration Committee 100%. The following table shows the individualised participation.

KEY TOPICS ADDRESSED BY THE SUPERVISORY BOARD

The following key topics formed the focus of the individual Supervisory Board meetings: At the meeting on January 21, 2020, the Executive Board mainly reported on the preliminary key figures for the fiscal year 2020 and the economic situation. The Supervisory Board also discussed the declaration on compliance submitted within the framework of the Corporate Governance Code. Furthermore, the risk report of the company, which describes the most important risk positions and the risk management in the group, was approved and the sustainability report was discussed. The Executive Board also provided information about further steps in China for the Radiopharma division and about current development projects. The main subject of the meeting on 27 March 2020 was the review of the annual financial statements and the management reports for the Group and the company. The Supervisory Board also approved the proposed resolutions on the remuneration system for the Executive Board and the agenda for the 2020 Annual General Meeting. The Supervisory Board also decided to establish a Remuneration Committee with immediate effect. The meeting on 10 June 2020 focused primarily on the business figures for the 1st quarter of 2020 and preparations for the Annual General Meeting. The Supervisory Board meeting on 11 August 2020 mainly discussed the business figures for the 2nd quarter of 2020 and ongoing projects, including the geopolitical expansion strategy in the Medical segment. The only item on the agenda of the meeting on 18 September 2020 was the discussion and resolution on the sale of shares in the tumour radiation business of Eckert & Ziegler BEBIG to the Chinese company TCL Healthcare Equipment. The focus of the meeting on 30 October 2020 was the presentation and approval of the budget for the 2021 financial year as well as the presentation of the business figures for the 3rd quarter of 2020. Further topics were the strategic orientation in the Medical and Isotope Products segments as well as the revision of rules of procedure for the Supervisory Board. In addition, a training event on the German Corporate Governance Code 2020 (DCGK) was held and the Declaration of Conformity with the German Corporate Governance Code was approved. The only item on the agenda of the meeting on 9 December 2020 was the strategic orientation of the Medical segment in the Chinese market.

COMMITTEE ACTIVITIES

In the reporting year, the Supervisory Board had one committee. The Remuneration Committee met once and prepared in particular the resolutions of the Supervisory Board on the determination of the performance criteria and the targets for the variable remuneration, the

determination and review of the appropriateness of the Executive Board remuneration and the approval of the remuneration report.

CORPORATE GOVERNANCE PRINCIPLES

In the period under review, the Supervisory Board continued to deal with the further development of the standards of good and responsible corporate governance, taking into account the German Corporate Governance Code as amended on February 7, 2017. On December 3, 2020, the Executive Board and the Supervisory Board issued a new Declaration of Conformity with the German Corporate Governance Code. Additional details regarding Corporate Governance are available in the Group's Corporate Governance Report, which is published on the Group's website in connection with the Declaration on Compliance. In the period under review, there were no conflicts of interest among members of the Supervisory Board.

EFFICIENCY REVIEW

The Supervisory Board regularly evaluates how effective it is as a body as a whole and how its committees perform their duties. A comprehensive review was conducted in September 2020. The results were discussed by the Supervisory Board in October. No significant deficiencies were identified. The next review is planned for the current financial year.

TRAINING AND CONTINUING EDUCATION

The members of the Supervisory Board are responsible for the training and continuing education measures required for their tasks, such as on changes in the legal framework, and are supported in this by the company. In the reporting year, an internal seminar on the new Corporate Governance Code 2020 was held as a dedicated training event on the topic of corporate governance.

AUDIT OF THE ANNUAL FINANCIAL STATEMENTS 2020

The annual financial statements of Eckert & Ziegler Strahlen- und Medizintechnik AG, the consolidated financial statements of the Eckert & Ziegler Group, and the management reports were audited, together with the accounting system, by the auditors appointed by the Annual General Meeting for fiscal year 2020, BDO AG Wirtschaftsprüfungsgesellschaft, Berlin, Germany. The auditor has concluded that all legal requirements have been met and has granted an unqualified auditor's opinion. Furthermore, the auditor has concluded that the Executive Board has implemented the measures incumbent upon it pursuant to Section 91 (2) of the German Stock Corporation Act (Aktiengesetz, AktG) regarding the establishment of a risk-monitoring system in a suitable form and that this system is suitable for the early detection of developments that endanger the continued existence of the company as a going concern. In regard to the report presented by the Executive Board on the company's relationships to affiliated enterprises in accordance with Section 312 AktG (affiliated company report), the auditor has confirmed that the statements made in the report are correct and that the payments made by the company for the legal transactions listed in the report were not inappropriately high. The annual financial statements, including the affiliated company report and the auditor's audit report, were submitted to the Supervisory Board. A representative of the auditor took part in the Supervisory Board's balance-sheet meetings on March 25, 2021 and on April 14, 2021 and reported on the key findings of the audit. The Supervisory Board acknowledged and approved the auditor's results. Based on its subsequent examination, the Supervisory Board raises no objections against the audited annual financial statements and the affiliated company report, including the Executive Board's concluding statement. The Supervisory Board therefore approved the annual financial statements of Eckert & Ziegler Strahlen- und Medizintechnik AG and the consolidated financial statements of the Eckert & Ziegler Group. The annual financial statements of Eckert & Ziegler Strahlen- und Medizintechnik AG are thereby adopted. The Supervisory Board concurs with the Executive Board's recommendation on the appropriation of net profit

ACKNOWLEDGMENT

The Supervisory Board would like to thank the Executive Board and all employees for their outstanding performance in the financial year 2020.

Berlin, April 2021

For the Supervisory Board

PROF DR WOLFGANG MAENNIG

Chairman of the Supervisory Board